CTKB VS EXAI Stock Comparison
Performance
CTKB10/100
10/100
CTKB returned -67.30% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
EXAI10/100
10/100
EXAI returned -18.14% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
CTKB46/100
46/100
CTKB receives a 46 of 100 based on 14 indicators. 6 are bullish, 7 are bearish.
EXAI71/100
71/100
EXAI receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
Earnings
CTKB43/100
43/100
CTKB has missed earnings 2 times in the last 20 quarters.
EXAI10/100
10/100
EXAI has missed earnings 5 times in the last 20 quarters.
Profit
CTKB38/100
38/100
Out of the last 15 quarters, CTKB has had 8 profitable quarters and has increased their profits year over year on 2 of them.
EXAI10/100
10/100
Out of the last 19 quarters, EXAI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
CTKB49/100
49/100
CTKB has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.
EXAI38/100
38/100
EXAI has had a lower than average amount of volatility over the last 12 months giving it a score of 38 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Cytek Biosciences, Inc. Common Stock Summary
Nasdaq / CTKB
Healthcare
Medical - Devices
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Exscientia Plc American Depositary Shares Summary
Nasdaq / EXAI
Healthcare
Biotechnology
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CTKB to other companies in the same or a similar industry.